Trials / Active Not Recruiting
Active Not RecruitingNCT04792073
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
A Phase II Single-Arm Clinical Trial Assessing Comprehensive Ablative Radiation Therapy With Avelumab in Unresectable and Metastatic Merkel Cell Carcinoma (CARTA)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the use of comprehensive ablative radiation therapy (CART), with the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has progressed after treatment and cannot be removed with surgery. The study researchers want to find out if CART works well when combined with avelumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab | Avelumab 800 mg given intravenously over 60 minutes (+20 minutes / -10 minutes) every 2 weeks (+/- 3 days) |
| RADIATION | Comprehensive Ablative Radiation Therapy | Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days |
Timeline
- Start date
- 2021-03-08
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2021-03-10
- Last updated
- 2026-04-07
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04792073. Inclusion in this directory is not an endorsement.